BYD Company Limited
002594
Contemporary Amperex Technology
300750
LONGi Green Energy Technology
601012
4
Hang Zhou Iron & Steel
600126
5
Jiangsu Changyou Environmental Protection Technology
301557
CN Stock MarketDetailed Quotes
688091 Shanghai Yizhong Pharmaceutical
- 40.02
- -0.58-1.43%
Trading Feb 28 09:40 CST
8.27BMarket Cap125.85P/E (TTM)
40.46High39.88Low4.39KlotVolume40.29Open40.60Pre Close17.64MTurnover0.21%Turnover Ratio51.18P/E (Static)206.59MShares53.1852wk High5.68P/B8.27BFloat Cap20.2752wk Low48.72Limit Up206.59MShs Float101.81Historical High32.48Limit Down1.43%Amplitude19.31Historical Low0.24Dividend TTM40.21Avg Price2.40KlotAsk0.59%Div YieldTTM100Lot Size1.29KlotBid
Shanghai Yizhong Pharmaceutical News
Shanghai Yizhong: Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on holding a performance briefing for the third quarter of 2024
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on holding a performance briefing for the third quarter of 2024
Announcement of Resolutions of the Eighth Meeting of the Second Board of Directors of Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong: Announcement of Resolutions of the 7th Meeting of the 2nd Supervisory Committee of Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong: Announcement of Resolutions of the 7th Meeting of the 2nd Board of Directors of Shanghai Yizhong Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 7th Meeting of the 2nd Board of Directors of Shanghai Yizhong Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 7th Meeting of the 2nd Board of Supervisors of Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong: Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on Obtaining a Notice of Approval for Drug Clinical Trials
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on obtaining a notice of approval for drug clinical trials
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on holding a 2024 semi-annual results briefing
Opinions of Guojin Securities Co., Ltd. on the initial public offering of some restricted shares by Shanghai Yizhong Pharmaceutical Co., Ltd. on the listing and circulation
Lawyer's opinion
Sinolink Securities Co., Ltd. continuous supervision and tracking report on Shanghai Yizhong Pharmaceutical Co., Ltd. in the first half of 2024.
Independent financial advisor report on the adjustment of the grant quantity and price of the restricted stock incentive plan for Shanghai Yizhong Pharmaceutical Co., Ltd. in 2022 by Sinolink Securities Co., Ltd.
Sinolink Securities Limited's verification opinion on Shanghai Yizhong Pharmaceutical Co., Ltd. and its wholly-owned subsidiary's use of part of the idle raised funds for cash management.
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. and its wholly-owned subsidiary's use of some idle raised funds for cash management.
Announcement of the Resolution of the 6th Meeting of the Second Supervisory Board of Shanghai Yizhong Pharmaceutical Co., Ltd.
Independent director's opinion
Announcement of resolutions of the sixth meeting of the second board of directors of Shanghai Yizhong Pharmaceutical Co., Ltd.
Special Report on the Use of Funds Raised in the First Half of 2024 by Shanghai Yizhong Pharmaceutical Co., Ltd.